Nano-Pulse Stimulation™ Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 Laser Medicine and Surgery Virtual Annual Conference

-- New Category Created for Non-Thermal Cellular Specific NPS Technology in Original ASLMS Program of Scientific Abstracts and Posters

HAYWARD, Calif.--(BUSINESS WIRE)--Jul. 1, 2020-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, today announced that three clinical studies demonstrating positive results across its dermatologic portfolio are available via webcast at the virtual annual conference of the American Society for Laser Medicine and Surgery (ASLMS). The virtual meeting went live on the ASLMS website on June 30, 2020. The clinical studies span the Company’s investigational use of NPS non-thermal energy in Nodular Basal Cell Carcinoma (BCC), Sebaceous Hyperplasia (SH) Lesions and Cutaneous Non-Genital Warts, along with e-Posters on pre-clinical observations of the effect of NPS energy on Murine Melanoma and Liver Tumors in situ.

“The robust body of clinical evidence demonstrated in the studies featured at the ASLMS virtual meeting outline the broad functional benefits of Nano-Pulse Stimulation technology in aesthetic and therapeutic dermatology. These results help to advance our goal of bringing a potentially paradigm-changing procedure to patients wishing to improve the health and appearance of their skin,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “We are especially grateful to our renowned scientific investigators for their research and for seamlessly adapting to a virtual presentation platform to highlight their important findings. We applaud the ASLMS for hosting an outstanding online educational event of this magnitude amid the COVID-19 pandemic.”

Dr. E. Victor Ross, Director of the Laser and Cosmetic Dermatology Center at Scripps Clinic in San Diego, Calif, discusses interim results of an expanded study of Nano-Pulse Stimulation technology for treating cutaneous, non-genital warts. According to Dr. Ross, this pivotal clinical study included additional sites, an increased number of subjects and the treatment of warts across more anatomic areas, which enabled broader use of NPS to treat this difficult group of skin lesions.

“Our interim findings of 87 treated warts on 27 patients showed improved efficacy with respect to high clearance ratings and no recurrence at 60 days after the last NPS treatment. Interestingly, NPS technology was particularly effective in clearing warts on the knees, hands, and legs,” said Dr. Ross. “Furthermore, no plume was reported in a sub-cohort of patient treatments, as confirmed by a particulate counter. This could be a major advantage over thermal modalities that produce a plume of vapor or smoke that can contain contaminated debris particles since protecting the health and safety of our patients is always our top concern."

Smoke or vapor plume is the byproduct of thermal-based procedures to treat skin tissue and can carry debris particles containing dust, chemicals, and infectious matter. While the use of ventilation systems, safe clinical practices and personal protective equipment are used, the absence of plume using NPS technology may provide an important additional benefit.


Members of ASLMS may access these presentations through the ASLMS Online Learning Center:



Lead Physician Author

Nodular Basal Cell Carcinoma Feasibility

A first-ever human feasibility study of Nano-Pulse Stimulation (NPS) to evaluate the potential elimination of a biopsy-confirmed nodular BCC in a short-term treat and resect study design

Thomas Rohrer, MD,
SkinCare Physicians of Chestnut Hill, MA
[Narrated slide presentation]




A Dose-Ranging, Multi-Center Pivotal Study Using the Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia

Girish (Gilly) Munavalli, MD,
Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, NC.
[Narrated slide presentation]

Warts Feasibility

Non-Thermal Nano-Pulse Stimulation (NPS) Technology for Treating Cutaneous, Non-Genital Warts: A Feasibility Study

E. Victor Ross, MD,
Laser and Cosmetic Dermatology Scripps Clinic San Diego, CA
[Narrated slide presentation]

NPS + Resiquimod in Murine Melanoma

Nano-Pulse Stimulation Technology in combination with the TLR agonist resiquimod synergies to eliminate murine melanoma

Brian Berman, MD, PhD,
Emeritus Professor of Dermatology and Internal Medicine, Department of Dermatology and Cutaneous Surgery at the University of Miami, FL

NPS Electron


In Situ


Nano-Pulse Stimulation Mechanism induces changes in the intracellular organelles in rat liver tumors treated in situ

Brian Zelickson, MD,
Associate Professor at the University of Minnesota Medical School and Director of its Electron Microscopy Laboratory

The American Society for Laser Medicine and Surgery has the ultimate responsibility for the planning, development, and content of continuing education programs and presentations, including those highlighted in this press release. Pulse Biosciences did not direct content or influence the planning or implementation of the ASLMS Online Learning Center. The spontaneous opinions expressed by speakers and participants during these activities belong to those individuals.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more, please visit

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among other things, statements relating to Nano-Pulse Stimulation technology including the effectiveness of such technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, Pulse Biosciences’ market opportunity, Pulse Biosciences’ expectations, whether stated or implied, regarding its planned rights offering, financing plans and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Additionally, you should not consider past results to be an indication of our future performance. Additional risks and uncertainties relating to the proposed offering, Pulse Biosciences and its business can be found under the heading “Risk Factors” in Pulse Biosciences’ most recent periodic, quarterly and annual reports filed with the SEC and in the accompanying prospectus relating to the offering to be filed with the SEC. Pulse Biosciences undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Investor Relations:
Pulse Biosciences, Inc.
Sandra Gardiner, EVP and CFO
Gilmartin Group
Philip Trip Taylor

Tosk Communications
Nadine D. Tosk

Source: Pulse Biosciences, Inc.